Turn Therapeutics (NASDAQ:TTRX) Upgraded at Zacks Research

Zacks Research upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Other research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a report on Monday, July 13th. D. Boral Capital reaffirmed a “buy” rating and set a $8.00 target price on shares of Turn Therapeutics in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Turn Therapeutics to a “hold” rating in a research note on Saturday, July 18th. Finally, LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Turn Therapeutics Price Performance

TTRX opened at $9.48 on Tuesday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $26.50. The stock has a market capitalization of $282.41 million and a PE ratio of -49.89. The stock’s 50 day moving average price is $6.81 and its 200-day moving average price is $4.85.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. On average, equities research analysts predict that Turn Therapeutics will post -0.09 EPS for the current year.

Institutional Trading of Turn Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Hodges Capital Management Inc. bought a new position in shares of Turn Therapeutics in the 4th quarter worth about $39,000. LPL Financial LLC bought a new stake in Turn Therapeutics during the fourth quarter worth about $51,000. Tamar Securities LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth about $59,000. Composition Wealth LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth about $63,000. Finally, Jane Street Group LLC bought a new position in shares of Turn Therapeutics during the fourth quarter valued at approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.